Detail akcie Nutra Pharma online

Business Summary: Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. The Company's drug candidates include RPI-MN and RPI-78M. Additionally, the Company markets drug products for sale for the treatment of pain under the brand Nyloxin and Pet Pain-Away. Its pain relief categories include arthritis pain, chronic back pain, headaches and migraines, and knee and joint pain. Its over the counter (OTC) homeopathic products include Nyloxin Topical Gel, Extra Strength Nyloxin Topical Gel, Nyloxin Oral Spray, Extra Strength Nyloxin Oral Spray, Nyloxin Topical Gel Roll On, Nyloxin Professional Size Pump Topical Gel and Pet Pain Away. The Company's holds approximately 21 patents in their portfolio.
Financial Summary: BRIEF: For the nine months ended 30 September 2022, Nutra Pharma Corp. revenues increased from $72K to $222K. Net income totaled $4.9M vs. loss of $15.3M. Revenues reflect Designer Diagnostic inc segment increase from $19K to $131K.